Natera

Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women’s health, and organ health. Founded in 2004, the company focuses on advancing personalized genetic diagnostics to improve standard-of-care interventions. By leveraging proprietary next-generation sequencing and software platforms like Constellation, Natera provides clinical laboratory services that enable earlier disease detection and targeted patient monitoring. Meet Natera's team to understand the leadership driving these innovations in molecular diagnostics.

Operating with 5,000-10,000 employees, Natera maintains a robust operational footprint across seven global locations. The company’s infrastructure supports complex clinical workflows, including carrier screening, non-invasive prenatal testing, and organ transplant monitoring. Learn about Natera's global headquarters for detailed geographic information regarding their primary facilities in Austin, Texas. Their commitment to data-driven health information and system integration ensures high-quality laboratory services for physicians and patients worldwide.

Publicly traded under the ticker NASDAQ: NTRA, the company demonstrates significant market presence within the competitive landscape of genetic testing. With annual revenue reaching $2.7B, Natera continues to scale its commercialization efforts and research initiatives. Explore financial highlights to review their funding history, debt structures, and growth metrics. As a key player in the biotechnology sector, Natera remains dedicated to transforming patient outcomes through accessible, high-precision genetic testing technology and comprehensive diagnostic solutions.